Chardan Capital analyst Daniil Gataulin maintained a Buy rating on Oculis Holding today and set a price target of $51.00. The company’s shares closed yesterday at $19.06.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Gataulin is a 4-star analyst with an average return of 14.5% and a 37.78% success rate. Gataulin covers the Healthcare sector, focusing on stocks such as uniQure, Kodiak Sciences, and Clearside Biomedical.
In addition to Chardan Capital, Oculis Holding also received a Buy from H.C. Wainwright’s Yi Chen in a report issued yesterday. However, on October 4, TR | OpenAI – 4o reiterated a Hold rating on Oculis Holding (NASDAQ: OCS).
OCS market cap is currently $1.01B and has a P/E ratio of -7.13.
Read More on OCS:
Disclaimer & DisclosureReport an Issue
- Oculis price target raised to $51 from $33 at Chardan
- Oculis price target raised to $30 from $28 at BofA
- Oculis price target raised to $36 from $33 at H.C. Wainwright
- Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology
- Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)